NCT07200583View on ClinicalTrials.gov

Protein A Immunoadsorption in Highly Sensitized Haplo-HSCT Patients

CompletedOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

May 31, 2025

Primary Completion Date

August 31, 2025

Study Completion Date

August 31, 2025

Conditions
Hematologic MalignanciesHematologic DisordersAllogeneic Hematopoietic Stem Cell Transplantation (HSCT)Graft Failure
Interventions
PROCEDURE

Protein A immunoadsorption

Extracorporeal therapy performed prior to haploidentical HSCT to remove donor-specific anti-HLA antibodies (DSA)

DRUG

Rituximab (optional, in some patients)

Anti-CD20 monoclonal antibody occasionally combined with immunoadsorption as part of desensitization strategy

DRUG

Bortezomib (optional, in some patients)

Proteasome inhibitor occasionally used in combination with desensitization therapy.

Trial Locations (1)

Unknown

The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian 350001, Fuzhou

All Listed Sponsors
lead

Ting YANG

OTHER